What Is Peripheral Artery Disease and How Does It Develop?
Peripheral artery disease (PAD) occurs when atherosclerotic plaque builds up in the arteries supplying the legs and feet, reducing blood flow and causing leg pain during walking. PAD affects over 8.5 million Americans and is a marker of systemic atherosclerosis, indicating significantly elevated risk of heart attack and stroke.
PAD involves the same disease process as coronary artery disease — atherosclerosis — but affects the peripheral arteries, most commonly in the legs. Cholesterol-rich plaque accumulates in artery walls over decades, progressively narrowing the vessel and reducing blood flow. When the muscles need more blood during walking, the narrowed arteries cannot deliver enough oxygen, causing cramping, aching, or fatigue known as intermittent claudication.
PAD is significantly underdiagnosed, with up to 40% of patients being asymptomatic. It is a powerful predictor of cardiovascular events — PAD patients have a 6-fold higher risk of cardiovascular death compared to the general population. The disease shares risk factors with coronary artery disease: smoking is the strongest modifiable risk factor, followed by diabetes, hypertension, and high cholesterol. Screening with the ankle-brachial index (ABI) is recommended for adults over 65 and those over 50 with risk factors.
What Should You Do If You Suspect Peripheral Artery Disease?
See your doctor for an ankle-brachial index (ABI) test — a painless, 15-minute screening that can diagnose PAD. If diagnosed, the immediate priorities are smoking cessation, starting antiplatelet and statin therapy, beginning a supervised exercise program, and managing blood pressure and blood sugar.
The ABI is the cornerstone diagnostic test for PAD. It compares systolic blood pressure at the ankle to that in the arm. An ABI of 0.91-1.30 is normal, 0.70-0.90 indicates mild PAD, 0.40-0.69 indicates moderate PAD, and below 0.40 indicates severe PAD. The test has a sensitivity of 95% and specificity of 100% for angiographically confirmed PAD. Screening is recommended for adults aged 65 and older, adults aged 50-64 with risk factors, and anyone with exertional leg symptoms.
Once diagnosed, aggressive cardiovascular risk reduction is paramount. PAD is a coronary artery disease equivalent — patients face the same cardiovascular event rates as those with established coronary disease. The AHA/ACC PAD guidelines recommend antiplatelet therapy (aspirin 75-325 mg or clopidogrel 75 mg), high-intensity statin therapy, blood pressure control below 130/80 mmHg, and glycemic management for diabetic patients. Smoking cessation is the single most impactful intervention, reducing all-cause mortality in PAD patients by up to 50%.
The ABI has sensitivity of 95% and specificity of 100% for angiographically confirmed PAD
What Causes Peripheral Artery Disease?
PAD is caused by atherosclerosis — the buildup of fatty plaques in the arteries supplying the legs. The same process that causes coronary artery disease narrows the peripheral arteries, reducing blood flow to the lower extremities. Smoking, diabetes, hypertension, and high cholesterol are the primary drivers of PAD development.
Atherosclerosis in PAD most commonly affects the superficial femoral and popliteal arteries (60-70% of cases), followed by the aortoiliac segment (25-30%) and tibial arteries (10-15%). The disease process is identical to coronary atherosclerosis — endothelial injury, lipid accumulation, inflammatory cell infiltration, and fibrous cap formation. Plaque progression gradually narrows the arterial lumen, reducing blood flow to the muscles during exercise and causing claudication.
Diabetes is a particularly important PAD risk factor, increasing risk 2-4 fold and being associated with more distal disease (tibial arteries), calcified lesions that are harder to treat, and higher amputation rates. The combination of PAD and diabetic neuropathy is especially dangerous because patients may not feel ischemic pain, presenting late with tissue loss. Chronic kidney disease is also a significant independent risk factor, with PAD prevalence exceeding 30% in dialysis patients.
How Is PAD Treated?
Treatment includes supervised exercise therapy as first-line for claudication, pharmacotherapy with cilostazol for symptom relief, aggressive cardiovascular risk reduction with statins and antiplatelets, and revascularization for severe or lifestyle-limiting disease unresponsive to conservative measures.
Supervised exercise therapy (SET) is recommended as first-line treatment for claudication by all major guidelines. A structured program of walking exercise performed 3-5 times weekly for 30-60 minutes, progressively increasing intensity to the point of moderate-to-severe claudication pain, improves maximal walking distance by 50-200%. A Cochrane meta-analysis of 32 trials confirmed SET significantly improves walking ability compared to usual care. The CLEVER trial demonstrated that SET was superior to stent revascularization for improving peak walking time at 18 months.
Cilostazol (Pletal) 100 mg twice daily is the only FDA-approved medication for claudication symptoms. It acts as a phosphodiesterase-3 inhibitor with vasodilatory, antiplatelet, and anti-proliferative effects. Meta-analyses show it improves maximal walking distance by approximately 50% compared to placebo. It is contraindicated in patients with heart failure. For critical limb ischemia — characterized by rest pain, ulceration, or gangrene — revascularization (endovascular or surgical bypass) is essential to prevent amputation.
The CLEVER trial demonstrated SET was superior to stent revascularization for improving peak walking time
What Are the Complications if Peripheral Artery Disease Is Left Untreated?
Untreated PAD can progress from intermittent claudication to critical limb ischemia (CLI), causing rest pain, non-healing ulcers, gangrene, and ultimately amputation. Because PAD is a marker of systemic atherosclerosis, untreated patients also face dramatically elevated risks of heart attack, stroke, and cardiovascular death.
Critical limb ischemia represents the most severe stage of PAD, occurring when blood flow is insufficient to meet the metabolic demands of tissue at rest. CLI affects approximately 1-2% of PAD patients annually and presents with rest pain (typically worse at night, relieved by dangling the leg), non-healing wounds or ulcers on the feet or toes, and in advanced cases, gangrene. Without revascularization, the 1-year amputation rate for CLI is 25-40%.
The cardiovascular consequences of untreated PAD are even more concerning than limb complications. PAD patients have a 6-fold higher risk of cardiovascular death compared to age-matched controls. Five-year cardiovascular mortality in symptomatic PAD is 20-30%, rising to 50% in CLI patients. These deaths are predominantly from myocardial infarction and stroke, reflecting the systemic nature of atherosclerotic disease.
Functional decline and reduced quality of life are significant but often overlooked consequences. Progressive claudication limits walking distance, daily activities, employment, and social participation. Depression affects up to 30% of PAD patients. Early treatment with supervised exercise, medical therapy, and cardiovascular risk reduction can slow progression and improve functional capacity.
- Critical limb ischemia with rest pain and non-healing wounds
- Gangrene requiring amputation (25-40% of CLI patients within 1 year without treatment)
- Heart attack (2-3 times higher risk than general population)
- Stroke (2-3 times higher risk)
- Cardiovascular death (6-fold increased risk)
- Progressive functional decline and reduced walking capacity
- [Rare] Acute limb ischemia from sudden arterial occlusion requiring emergency surgery
How Can You Live Well With Peripheral Artery Disease?
Living well with PAD centers on three pillars: a structured walking exercise program to improve circulation, comprehensive cardiovascular risk factor management, and daily foot care to prevent wounds and infections. Most PAD patients can maintain active, fulfilling lives with proper treatment and self-management.
A consistent walking program is the foundation of PAD self-management. Walk daily, even on days when claudication is present — the discomfort does not cause harm. Gradually increase your walking distance over weeks to months. Many patients double or triple their pain-free walking distance within 3-6 months of starting a structured program. Consider joining a supervised exercise program if available, as outcomes are superior to unsupervised walking.
Daily foot inspection is critical, especially for patients with diabetes or neuropathy. Check feet for cuts, blisters, redness, swelling, or skin color changes every day. Moisturize dry skin but avoid between toes. Wear well-fitting shoes with good support. Never walk barefoot. Report any non-healing wound or skin change to your healthcare provider promptly, as early intervention prevents complications.
Cardiovascular risk factor management is equally important for preventing heart attacks and strokes. Take all prescribed medications consistently — statins, antiplatelets, and blood pressure medications are essential. If you smoke, quitting is the single most impactful change you can make, reducing amputation risk by up to 50%. Emotional support through PAD support groups and counseling can address the depression and anxiety that commonly accompany chronic vascular disease.
What Questions Should You Ask Your Doctor About Peripheral Artery Disease?
Asking informed questions helps you take an active role in your PAD management and ensures you receive comprehensive vascular care. Bring this list to your next appointment to guide the conversation about your diagnosis, treatment plan, and long-term outlook.
Your doctor can help you understand the severity of your PAD, tailor treatment to your specific situation, and monitor for disease progression. Regular follow-up, including periodic ABI testing, ensures that your treatment plan remains effective and that any worsening is caught early.
- What is my ABI number and what does it mean for my PAD severity? — Knowing your baseline ABI helps you track disease progression over time
- Should I be in a supervised exercise therapy program? — SET has stronger evidence than unsupervised walking and may be covered by insurance
- Am I on all the recommended medications (statin, antiplatelet, blood pressure)? — Medication optimization reduces cardiovascular events by 30-50%
- How often should my legs and feet be examined? — Regular vascular assessments catch progression before complications develop
- Do I also need screening for coronary artery disease or carotid stenosis? — PAD patients often have atherosclerosis in multiple vascular beds
- What wound care resources are available if I develop a foot ulcer? — Early access to wound care specialists dramatically improves healing rates
